Cleveland receives notice of allowance from FDA to initiate phase I trial of Protectan CBLB-502 Aug. 8, 2008
Novel kappa opioid receptor antagonist zyklophin has therapeutic potential in drug abuse July 18, 2008
Sublingual buprenorphine safe and effective in controlling neonatal abstinence syndrome July 17, 2008
RSS